文献类型：期刊文献

中文题名：升陷汤对肺纤维化大鼠肺功能及肺组织、血清肺表面活性物质相关蛋白D表达的影响

英文题名：Effects of Shengxian Decoction on pulmonary function, lung tissue and serum of pulmonary surfactant protein D expression in pulmonary fibrosis rats

作者：张旭辉[1];刘喜平[1,2];孙杰[3];王庆胜[1];武妍琳[1];马泉[1];张皓珍[1]

第一作者：张旭辉

机构：[1]甘肃中医药大学附属医院肺病科,兰州730000;[2]甘肃中医药大学基础医学院,兰州730000;[3]广州中医药大学第一附属医院呼吸内科,广州510405

第一机构：甘肃中医药大学第二附属医院

年份：2021

卷号：36

期号：11

起止页码：6714

中文期刊名：中华中医药杂志

外文期刊名：China Journal of Traditional Chinese Medicine and Pharmacy

收录：CSTPCD;;北大核心:【北大核心2020】；CSCD:【CSCD2021_2022】；

基金：甘肃省自然科学基金项目(No.20JR5RA165)。

语种：中文

中文关键词：升陷汤;博莱霉素;肺纤维化;肺功能;血气分析;肺表面活性物质相关蛋白D

外文关键词：Shengxian Decoction;Bleomycin;Pulmonary fibrosis(PF);Pulmonary function;Blood gas analysis;Pulmonary surfactant protein D(SP-D)

摘要：目的:观察升陷汤对博来霉素诱导的肺纤维化模型大鼠肺功能及肺组织、血清肺表面活性物质相关蛋白D(SP-D)表达的影响。方法:SPF级雄性SD大鼠60只,随机分为正常组,模型组,升陷汤高、中、低剂量组及吡非尼酮组,每组10只。除正常组外,其余大鼠采用气管内注射博莱霉素建立肺纤维化模型,造模后第8天起,高、中、低剂量组分别以10.4、5.2、2.6g/kg升陷汤灌胃,吡非尼酮组予0.12g/kg吡非尼酮混悬液灌胃,连续28d后,用动物肺功能仪检测肺活量(FVC)、1秒用力呼气容积(FEV1)、1秒钟用力呼气量占用力肺活量比值(FEV1%)、肺一氧化碳弥散量(DLCO)、呼气峰值流速(PEF);血气分析仪检测腹主动脉氧分压(PO;)、二氧化碳分压(PCO;)、氧饱和度(SO;);Masson染色观察肺组织的纤维化程度,计算胶原容积分数(CVF),免疫组化法检测肺组织SP-D的表达,ELISA法检测血清中SP-D的含量。结果:与正常组比较,模型组大鼠肺功能FVC、FEV1、DLCO、PEF及PaO;、SO;显著降低(P<0.05),FEV1%及PaCO;显著升高(P<0.05),肺组织CVF增加(P<0.05),肺组织中SP-D表达下降,血清SP-D含量升高(P<0.05);与模型组比较,升陷汤高、中、低剂量组均能升高FVC、FEV1、DLCO、PEF及PaO;、SO;(P<0.05),降低FEV1%及PaCO;(P<0.05),降低肺组织CVF(P<0.05),升陷汤高、中剂量组肺组织中SP-D表达升高,血清SP-D含量降低(P<0.05)。结论:升陷汤能改善实验性肺纤维化模型大鼠肺功能,其作用机制与升高肺组织SP-D表达,降低血清SP-D含量有关。
Objective: To observe the effect of Shengxian Decoction on pulmonary function and expression of pulmonary surfactant protein D(SP-D) in lung tissue and serum of bleomycin induced pulmonary fibrosis model rats. Methods: Sixty male SD rats of SPF grade were randomly divided into normal group, model group, high, medium and low dose groups of Shengxian Decoction and pirfenidone group, with 10 rats in each group. In addition to the normal group, the remaining rats were injected with bleomycin to establish the pulmonary fibrosis model. From the 8 th day after the model was established, the high, medium and low doses of 10.4, 5.2, 2.6 g/kg Shengxian Decoction were given to the rats respectively. In the pirfenidone group, 0.12 g/kg pirfenidone suspension was given to the rats for gavage. After 28 days, vital capacity(FVC), forced expiratory volume in one second(FEV1),ratio of forced expiratory volume to forced vital capacity in one second(FEV1%), pulmonary carbon monoxide diffusion capacity(DLCO) and peak expiratory flow rate(PEF) were measured by the animal lung function instrument, oxygen partial pressure(PO;),carbon dioxide partial pressure(PCO;) and oxygen saturation(SO;) in abdominal aorta were measured by blood gas analyzer, the degree of fibrosis in lung tissue was observed by Masson, and SP-D was detected by immunohistochemistry, the content of SP-D in serum was detected by enzyme-linked immunosorbent assay(ELISA). Results: Compared with the normal group, FVC, FEV1,DLCO, PEF, PaO;, SO;in the model group were significantly reduced(P<0.05), FEV1% and PaCO;were significantly increased(P<0.05), collagen volume fraction in lung tissue was increased(P<0.05), SP-D expression in lung tissue was decreased, and SP-D content in serum was increased(P<0.05);Compared with the model group, high, medium and low dose shengxiantang could increase FVC, FEV1, DLCO, PEF, PaO;, SO;(P<0.05), reduce FEV1% and PaCO;(P<0.05), reduce collagen volume fraction(P<0.05), the high and medium dose Shengxiantang could increase SP-D expression in lung tissue, and decrease SP-D content in serum(P<0.05). Conclusion: Shengxian Decoction can improve the pulmonary function of rats with experimental pulmonary fibrosis. Its mechanism is related to reducing the degree of pulmonary fibrosis, increasing the expression of SP-D in lung tissue,and reducing the content of SP-D in serum to protect lung tissue.